17515-66-1Relevant academic research and scientific papers
Reaction of ethyl 4,4,4-trifluoroacetoacetate enolate with 3-bromo-1,1,1-trifluoroacetone: Synthesis of 2,4-bis (trifluoromethyl) furan
Smith, Jonathan O.,Mandal, Braja K.,Filler, Robert,Beery, James W.
, p. 123 - 128 (1997)
The potassium enolate of ethyl 4,4,4-trifluoroacetoacetate 1 reacts with 3-bromo-1,1,1-trifluoroacetone 2 in DMSO solution to yield three products. Ethyl 2,4-bis(trifluoromethyl)-4-hydroxydihydro-3-furoate 3 is generated via C-acylation. The hydrated trifluoromethyl ketone 4 is formed by O-alkylation and 4 reacts further with 2 to give the di-O-alkylated ketone hydrate 5. Compound 3 undergoes dehydration to the furan derivative 6 on reaction with Ac2O-ZnCl2.
Discovery of Novel Inhibitors of Uridine Diphosphate- N-Acetylenolpyruvylglucosamine Reductase (MurB) from Pseudomonas aeruginosa, an Opportunistic Infectious Agent Causing Death in Cystic Fibrosis Patients
Abell, Chris,Blundell, Tom L.,Brown, Karen P.,Coyne, Anthony G.,Di Pietro, Ornella,Floto, R. Andres,Hess, Jeannine,Holland, Matthew T. O.,Kim, So Yeon,Marchetti, Chiara,Mendes, Vitor,Acebrón-García-De-Eulate, Marta,Mayol-Llinàs, Joan
, p. 2149 - 2173 (2022/02/14)
Pseudomonas aeruginosa is of major concern for cystic fibrosis patients where this infection can be fatal. With the emergence of drug-resistant strains, there is an urgent need to develop novel antibiotics against P. aeruginosa. MurB is a promising target
PYRROL-1 -YL BENZOIC ACID DERIVATES USEFUL AS MYC INHIBITORS
-
Paragraph 00335; 00348, (2014/05/24)
The present invention provides compounds of Formula (I-A), (I-B), and (I-C), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting Myc (e.g., c-Myc) activity. The p
AMINOETHANOL DERIVATIVES
-
Page/Page column 125, (2010/11/30)
The present invention provides a pharmaceutical agent having cholesteryl ester transfer protein inhibitory action and useful as a blood lipid lowering agent and the like. The present invention relates to a compound represented by the formula wherein Ar1 is an aromatic ring group optionally having substituents, Ar2 is an aromatic ring group having substituents, OR'' is an optionally protected hydroxyl group, R is an acyl group, R' is a hydrogen atom or a hydrocarbon group optionally having substituents, or a salt thereof, and a pharmaceutical composition containing a compound of the formula (I) or a salt thereof or a prodrug thereof.
